Please assess the completion status of the following clinical trial:

Trial Title: Comparing Quetiapine XR Monotherapy and Augmentation With Lithium Augmentation in TRD Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Documented clinical diagnosis as confirmed by the M.I.N.I. meeting criteria from the Diagnostic and Statistical Manual of Mental disorders, 4th Edition (DSM-IV) for any of the following:296.2x MDD, Single Episode296.3x MDD, Recurrent Episode~* Current episode of depression present, at least 42 days prior to enrolment but not more than 18 months~* MADRS-Score ≥ 25 at enrolment and randomisation~Exclusion Criteria:~* Patients with a DSM-IV Axis I disorder other than MDD within 6 months of randomisation~* Patients with a diagnosis of DSM-IV Axis II disorder which has a major impact on the patient's current psychiatric status~* Patients who, in the investigator's judgment pose a current serious suicidal or homicidal risk, or have made a suicide attempt within the past 6 months

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Add-on Quetiapine XR+SSRI/Venlafaxine (Type: ACTIVE_COMPARATOR): Selective serotonin reuptake inhibitors (SSRI) or Venlafaxine from previous therapy + add-on treatment with quetiapine XR, 300mg tablet once daily (od).~From previous anti-depressant treatment 64% of the patients had SSRI and 35% had Venlafaxine at baseline.
- Add-on Lithium+SSRI/Venlafaxine (Type: ACTIVE_COMPARATOR): Selective serotonin reuptake inhibitors (SSRI) or venlafaxine from previous therapy + add-on treatment with lithium, approximately 900mg tablet once daily (od).~From previous anti-depressant treatment 67% of the patients had SSRI and 33% had Venlafaxine at baseline.
- Monotherapy Quetiapine XR (Type: ACTIVE_COMPARATOR): Switch from previous treatment with SSRI or venlafaxine to quetiapine XR monotherapy, 300mg tablet once daily (od)

Based on this trial design, predict the completion outcome and termination type (if applicable).